CBIOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (31 10月 2023 @ 05:00):

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation...

Stats
本日の出来高	460 710
平均出来高	437 269
時価総額	19.42M
EPS	$0 ( 2024-04-04 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0.240 ( 2023-01-13 )
Next Dividend	$0 ( N/A )
P/E	-0.0247
ATR14	$0.0370 (7.24%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Luo Ying	Buy	3 350 897	Stock Option (Right to Buy)
2023-10-30	Luo Ying	Buy	2 840 376	Common Stock
2023-11-20	Luo Ying	Buy	2 262 755	Stock Option (Right to Buy)
2023-11-20	Ye Weiguo	Buy	1 665 115	Stock Option (Right to Buy)
2023-11-20	Ma Songjiang	Buy	4 510 047	Stock Option (Right to Buy)

INSIDER POWER
24.25
Last 85 transactions
Buy: 88 748 347 \| Sell: 111 334 812

ボリューム相関

長: -0.02 (neutral)

短: -0.30 (neutral)

Signal:(55.246) Neutral

Catalyst Biosciences Inc 相関

10 最も正の相関
CALA	0.925
ODT	0.917
UPC	0.909
BCAB	0.908
NBIX	0.897
LLNW	0.891
ENNV	0.891
LFMD	0.891
XPDI	0.889
YJ	0.889

10 最も負の相関
SHC	-0.922
WYNN	-0.921
DSPG	-0.917
ACLS	-0.913
PPD	-0.908
BNIX	-0.907
DUNE	-0.906
RVNC	-0.902
HHGC	-0.901
FWONK	-0.899

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Catalyst Biosciences Inc 相関 - 通貨/商品

-0.38
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.37
( neutral )

0.22
( neutral )

0.51
( weak )

Catalyst Biosciences Inc 財務諸表

Annual	2022
収益:	$794 000
総利益:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2022
収益:	$794 000
総利益:	$-4 000.00 (-0.50 %)
EPS:	$-0.260

FY	2021
収益:	$0.00
総利益:	$-7.38M (0.00 %)
EPS:	$-2.87

FY	2020
収益:	$20.95M
総利益:	$11.79M (56.26 %)
EPS:	$-2.93

Financial Reports:

No articles found.

Catalyst Biosciences Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$1.430 (N/A)	$0 (N/A)	$0.240 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Catalyst Biosciences Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 1.002 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$59.77	2015-08-20
Last Dividend	$0.240	2023-01-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$61.44	--
Avg. Dividend % Per Year	39.53%	--
Score	4.37	--
Div. Sustainability Score	0
Div.Growth Potential Score	1.002
Div. Directional Score	0.464	--

Next Divdend (Est)
(2027-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

4.37

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2015	$59.77	22.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$1.430	143.00%
2023	$0.240	41.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	55.72	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	-0.709	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	12.04	1.500	10.00	10.00	[0.1 - 1]
payoutRatioTTM	-0.289	-1.000	-2.89	2.89	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-71.39	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
freeCashFlowPerShareTTM	-0.352	2.00	-0.176	-0.352	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	3.15	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	55.75	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	-0.0127	0.800	-3.42	-2.73	[0.5 - 2]
Total Score				-0.0749

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.439	1.000	-0.145	0	[1 - 100]
returnOnEquityTTM	12.04	2.50	10.00	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.352	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.352	2.00	-0.117	-0.235	[0 - 30]
payoutRatioTTM	-0.289	1.500	-2.89	2.89	[0 - 1]
pegRatioTTM	-0.00352	1.500	-3.36	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	16.85	1.000	10.00	0	[0.1 - 0.5]
Total Score				1.002

Catalyst Biosciences Inc

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.